- Home
- OXSQ vs LYEL Comparison
OXSQ vs LYEL Comparison
Compare OXSQ & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- LYEL
- Stock Information
- Founded
- OXSQ 2003
- LYEL 2018
- Country
- OXSQ United States
- LYEL United States
- Employees
- OXSQ N/A
- LYEL N/A
- Industry
- OXSQ Blank Checks
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- OXSQ Finance
- LYEL Health Care
- Exchange
- OXSQ Nasdaq
- LYEL Nasdaq
- Market Cap
- OXSQ 175.2M
- LYEL 203.9M
- IPO Year
- OXSQ N/A
- LYEL 2021
- Fundamental
- Price
- OXSQ $2.61
- LYEL $0.58
- Analyst Decision
- OXSQ
- LYEL Sell
- Analyst Count
- OXSQ 0
- LYEL 2
- Target Price
- OXSQ N/A
- LYEL $1.00
- AVG Volume (30 Days)
- OXSQ 556.5K
- LYEL 1.1M
- Earning Date
- OXSQ 03-14-2025
- LYEL 02-26-2025
- Dividend Yield
- OXSQ 16.09%
- LYEL N/A
- EPS Growth
- OXSQ N/A
- LYEL N/A
- EPS
- OXSQ N/A
- LYEL N/A
- Revenue
- OXSQ $44,787,853.00
- LYEL $63,000.00
- Revenue This Year
- OXSQ N/A
- LYEL N/A
- Revenue Next Year
- OXSQ N/A
- LYEL N/A
- P/E Ratio
- OXSQ N/A
- LYEL N/A
- Revenue Growth
- OXSQ N/A
- LYEL N/A
- 52 Week Low
- OXSQ $2.40
- LYEL $0.55
- 52 Week High
- OXSQ $3.29
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- OXSQ 52.27
- LYEL 34.70
- Support Level
- OXSQ $2.51
- LYEL $0.55
- Resistance Level
- OXSQ $2.70
- LYEL $0.62
- Average True Range (ATR)
- OXSQ 0.05
- LYEL 0.04
- MACD
- OXSQ 0.02
- LYEL 0.01
- Stochastic Oscillator
- OXSQ 70.00
- LYEL 14.24
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing, and Diversified Insurance.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.